Treatment Options for Patients Who Have Antiphospholipid Syndromes

Hematology/Oncology Clinics of North America

Volumn 22, Issue 1, 2008, Pages 145-153

  Bick, Rodger L ^a   Baker, William F ^b,c,d  

^a Medicine Center for Health Sciences University of California Los Angeles ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KERN MEDICAL CENTER   (United States)

^d California Clinical Thrombosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADD ON THERAPY; ALLERGIC REACTION; ALOPECIA; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; AORTA THROMBOSIS; ARTERY THROMBOSIS; CAROTID ARTERY THROMBOSIS; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG SUBSTITUTION; EOSINOPHILIA; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SKIN MANIFESTATION; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TRANSAMINASEMIA; TREATMENT PLANNING; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; VENOUS THROMBOSIS;

EID: 38349018448     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.10.010     Document Type: Review

References (26)

1. Bick R.L. Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Int J Hematol 65 (1997) 193-213
2. Bick R.L. The antiphospholipid thrombosis syndromes: a common multidisciplinary medical problem. J Clin Appl Thromb Hemost 3 (1997) 270-283
3. Bick R.L. Hereditary and acquired thrombophilia. Clin Appl Thromb Hemost 12 (2006) 125-135
4. Bick R.L. Recurrent miscarriage syndrome and Infertility caused by blood coagulation protein / platelet defects. Chapter 2. In: Bick R.L., Frenkel E., and Baker W. (Eds). Hematological complications in obstetrics, pregnancy and gynecology (2006), Cambridge University Press, Cambridge (UK) 55-74
5. Walenga J.M., and Bick R.L. Heparin-induced thrombocytopenia, paradoxical thromboembolism and other side effects of heparin therapy. Med Clin North Am 82 3 (1998) 635-658
6. Girolami B., Prandoni P., Rossi L., et al. Transaminase elevation in patients treated with unfractionated heparin or low molecular weight heparin for venous thromboembolism. Clin Appl Thromb Hemost 4 (1998) 126-128
7. Bick R.L. Antiphospholopid thrombosis syndromes. Hematol Oncol Clin North Am 17 (2003) 115-147
8. Schved J.F., Dupuy-Fons C., and Biron C. A prespective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipiod (MAP) Study. Haemostasis 24 (1994) 175-182
9. Vila P., Hernandez M.C., and Lopez-Fernandez M.F. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72 (1994) 209-213
10. Bick R.L., and Baker W.F. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 18 (1992) 267-274
11. Asherson R.A., Cervera R., de Groot P.G., et al. Catastrophic and antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 7 (2003) 530-534
12. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 3 (1998) 195-207
13. Harris E.N., Gharavi A., Hegde U., et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol 59 2 (1985) 231-234
14. Matsuda J., Sanaka T., Gonichi K., et al. Occurence of thrombotic thrombocytopenic purpura in a systemic lupus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand-factor cleaving protease. Lupus 11 (2002) 463-464
15. Schulman S., Svenungsson E., Granqvist S., et al. Anticardolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104 (1998) 332-338
16. Khamashta M., Cuadrado M., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
17. Nzerue C., Hewan-Lowe K., Pierangeli S., et al. "Black swan in the kidney:" renal involvement in the antiphospholipid antibody syndrome. Kidney Int 62 (2002) 733-744
18. Dunn J., Noorily S., Petri M., et al. Antiphospholipid antibodies and retinal vascular disease. Lupus 5 (1996) 313-322
19. Nochy D., Daugas E., Droz D., et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10 3 (1999) 507-518
20. Carhuapoma J., Mitsias P., and Levine S.R. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 28 (1997) 2363-2369
21. Deschiens M., Conrad J., Horellou M., et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 27 (1996) 1724-1729
22. Provenzale J.M. Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: image findings. AJR 165 (1995) 365-368
23. Bick R., and baker W. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 25 (1999) 333
24. Group TAAiSSA. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurology 43 (1993) 2069-2073
25. Group TAAiSSA. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 48 (1997) 91
26. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002) 1019-1027